In the study conducted by Liolios et al. [28], the prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) were considered as valuable biological targets for the molecular imaging and therapy of prostate (PCa) and breast (BCa) cancer. This evidence concerns the gene GRPR and medical procedure.